The commission has decided to restrict use of the product to individuals over 60 years old who have certain health conditions. However, the UK health agency, the MHRA, has confirmed that the benefit-risk profile of Ixchiq remains favorable for people aged 18 to 59 who are at risk of infection by this virus and who do not have the underlying medical conditions that would contraindicate its use.

This update follows a temporary suspension by the MHRA regarding the use of this vaccine in elderly individuals, after reports of serious adverse effects, primarily among older people with significant comorbidities, during a vaccination campaign conducted in response to an epidemic outbreak on the island of La Réunion.